Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases

Spivacow, Francisco Rodolfo; Zanchetta, J. R.; Kerzberg, Eduardo; Frigeri, Adriana; Fiasché, Roxana; Roldán, Emilio J. A.

doi:10.1016/s0011-393x(96)80006-3

Cited by 8 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upper gastrointestinal tract safety is of particular interest because of adverse effects noted during clinical use with the bisphosphonates alendronate and pamidronate. 14,15,30,31 Although some studies of bisphosphonates have excluded subjects with specific gastrointestinal disorders, 9,10,12 our study did not; approximately 35% of the subjects in this trial had a history of or ongoing gastrointestinal disorders at study entry. It is reassuring that the gastrointestinal safety profile of risedronate in this trial was good despite the inclusion of these subjects.…”

Section: Bone Safetymentioning

confidence: 78%

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Harris¹

1999

JAMA

2,252

1,346

View full text Add to dashboard Cite

show abstract

Section: Bone Safetymentioning

confidence: 78%

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Harris¹

1999

JAMA

2,252

1,346

View full text Add to dashboard Cite

show abstract

“…Esophageal erosions and ulcerative esophagitis have been reported during clinical use of some bisphosphonates [8,9,[30][31][32]. Because gastrointestinal side effects have been an issue with some bisphosphonates, we included patients with previous or current gastrointestinal disease or who were users of NSAIDs or aspirin.…”

Section: Discussionmentioning

confidence: 99%

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Reginster

Minne²,

Sørensen

et al. 2000

Osteoporosis International

1,441

833

View full text Add to dashboard Cite

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease.

show abstract

“…Considering the local GI irritating activity of these compounds, essential for their absorption, it is easy to explain the digestive discomfort frequently reported by patients taking these drugs and the occurrence of GI AE [18,19,31,32]; however, as we will see further, the pathophysiology is more complex than local inflammation alone.…”

Section: Bisphosphonate Absorptionmentioning

confidence: 99%

The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment

2014

View full text Add to dashboard Cite

Osteoporotic fractures are a public health problem and their incidence and subsequent economic and social costs are expected to rise in the next future. Different drugs have been developed to reduce osteoporosis and the risk of osteoporotic fractures, and among them, antiresorptive agents, and in particular oral alendronate, are the most widely utilized. However, one of the most common problems with antiresorptive drugs is poor adherence to treatment, which is associated with a high fracture incidence and with an increase in hospitalization costs. One of the main reasons of poor adherence to these treatments is the occurrence of adverse events, mainly at gastrointestinal (GI) level, including dyspepsia, dysphagia, and esophageal ulcers. In light of these considerations the aim of this paper is to perform a literature review to show the pathophysiologic bases of GI alendronate-induced adverse events and how new bisphosphonate formulations like effervescent alendronate can improve compliance and persistence to treatment and decrease the fracture rate incidence in osteoporotic patients.

show abstract

Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases

Cited by 8 publications

References 14 publications

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

The potential impact of new effervescent alendronate formulation on compliance and persistence in osteoporosis treatment

Contact Info

Product

Resources

About